India, Sept. 2 -- Healthcare technology company Medtronic plc (MDT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted two regulatory milestones for its MiniMed 780G system. The agency cleared the SmartGuard algorithm as an interoperable automated glycemic controller (iAGC), allowing integration with Abbott's Instinct sensor for type 1 diabetes, and approved the MiniMed 780G system for use in adults 18 and older with insulin-requiring type 2 diabetes.
"These milestones mark an important next step in our work to bring the proven performance and outcomes of our MiniMed 780G automated insulin delivery system to more people living with diabetes. By enabling integration with the Instinct sensor and expanding the Mini...